Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus X TROZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus X TROZINE.
KETOTIFEN FUMARATE vs X-TROZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
X-TROZINE acts as a selective serotonin reuptake inhibitor (SSRI) by binding to the serotonin transporter (SERT) and blocking reuptake of serotonin, thereby increasing serotonergic neurotransmission.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
100 mg orally twice daily
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal excretion accounts for 60-70% of total clearance, predominantly as unchanged drug. Biliary/fecal elimination constitutes 20-30% via P-glycoprotein-mediated transport. Minor metabolism (<10%) via CYP3A4.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine